Effects of genetic polymorphisms of CYP2J2, CYP2C9, CYP2C19, CYP4F2, CYP4F3 and CYP4A11 enzymes in preeclampsia and gestational hypertension

[1]  Yee Ming Lee,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update , 2022, Clinical pharmacology and therapeutics.

[2]  R. V. van Schaik,et al.  Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs , 2021, European Journal of Human Genetics.

[3]  J. Valdivielso,et al.  Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy , 2021, Journal of clinical medicine.

[4]  S. Riaz,et al.  Association of CYP2C19*2 and *17 genetic variants with hypertension in Pakistani population , 2021 .

[5]  Yali Hu,et al.  Placenta-derived IL-32β activates neutrophils to promote preeclampsia development , 2021, Cellular & Molecular Immunology.

[6]  D. Lawlor,et al.  Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women , 2020, Nature Communications.

[7]  F. McCarthy,et al.  Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health? , 2020, Frontiers in Endocrinology.

[8]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing , 2020, Clinical pharmacology and therapeutics.

[9]  Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. , 2020, Obstetrics and gynecology.

[10]  L. Gong,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs , 2020, Clinical pharmacology and therapeutics.

[11]  Liyuan Peng,et al.  Metabolomics revealed decreased level of omega‐3 PUFA‐derived protective eicosanoids in pregnant women with pre‐eclampsia , 2019, Clinical and experimental pharmacology & physiology.

[12]  Ç. Yıldız,et al.  Epoxyeicosatrienoic acid Metabolism in Preeclampsia , 2018, Cumhuriyet Medical Journal.

[13]  V. Stepanov,et al.  A comprehensive study revealed SNP–SNP interactions and a sex-dependent relationship between polymorphisms of the CYP2J2 gene and hypertension risk , 2018, Hypertension Research.

[14]  S. Olsen,et al.  Fat intake during pregnancy and risk of preeclampsia: a prospective cohort study in Denmark , 2018, European Journal of Clinical Nutrition.

[15]  Tao Zhang,et al.  Genetic role of CYP4A11 polymorphisms in the risk of developing cardiovascular and cerebrovascular diseases , 2018, Annals of human genetics.

[16]  N. Sotoodehnia,et al.  Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes , 2018, International journal of molecular sciences.

[17]  Zhonghui Xie,et al.  Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation , 2018, BMC Cardiovascular Disorders.

[18]  K. Wallace,et al.  Arachidonic acid metabolites of CYP4A and CYP4F are altered in women with preeclampsia. , 2018, Prostaglandins & other lipid mediators.

[19]  R. Touyz,et al.  Downregulated Serum 14, 15-Epoxyeicosatrienoic Acid Is Associated With Abdominal Aortic Calcification in Patients With Primary Aldosteronism , 2018, Hypertension.

[20]  Heui-Soo Kim,et al.  Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE). , 2018, Prostaglandins, leukotrienes, and essential fatty acids.

[21]  U. Yasar,et al.  Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease , 2017, Basic & clinical pharmacology & toxicology.

[22]  Robert N. Taylor,et al.  The role of soluble epoxide hydrolase in preeclampsia. , 2017, Medical hypotheses.

[23]  L. Amaral,et al.  Selective inhibition of 20-hydroxyeicosatetraenoic acid lowers blood pressure in a rat model of preeclampsia. , 2017, Prostaglandins & other lipid mediators.

[24]  M. Owens,et al.  Pathophysiology and Current Clinical Management of Preeclampsia , 2017, Current Hypertension Reports.

[25]  Y. Izumiya,et al.  CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina , 2017, International journal of cardiology. Heart & vasculature.

[26]  G. Zanconato,et al.  Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta , 2016, Journal of hypertension.

[27]  Matthew R. Elliott,et al.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. , 2016, Frontiers in bioscience.

[28]  Qiang Zhou,et al.  Interaction Between CYP4F2 rs2108622 and CPY4A11 rs9333025 Variants Is Significantly Correlated with Susceptibility to Ischemic Stroke and 20-Hydroxyeicosatetraenoic Acid Level. , 2016, Genetic testing and molecular biomarkers.

[29]  Brian R. Phillips,et al.  Pharmacokinetics of metoprolol during pregnancy and lactation , 2016, Journal of clinical pharmacology.

[30]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP4F2 , 2015, Pharmacogenetics and genomics.

[31]  O. Gokcumen,et al.  Whole genome sequencing of Turkish genomes reveals functional private alleles and impact of genetic interactions with Europe, Asia and Africa , 2014, BMC Genomics.

[32]  Qian Li,et al.  Effect of 20-hydroxyeicosatetraenoic acid on biological behavior of human villous trophoblasts and uterine vascular smooth muscle cells. , 2014, Molecular medicine reports.

[33]  D. Mack,et al.  Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric Crohn's disease. , 2014, Gastroenterology.

[34]  H. Cui,et al.  Association of a CYP4A11 polymorphism and hypertension in the Mongolian and Han populations of China. , 2014, Genetics and molecular research : GMR.

[35]  J. Mcgiff,et al.  Maternal and fetal epoxyeicosatrienoic acids in normotensive and preeclamptic pregnancies. , 2013, American journal of hypertension.

[36]  Kwang-Hyeon Liu,et al.  LC-MS/MS for the simultaneous analysis of arachidonic acid and 32 related metabolites in human plasma: Basal plasma concentrations and aspirin-induced changes of eicosanoids. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[37]  U. Hodoğlugil,et al.  Turkish Population Structure and Genetic Ancestry Reveal Relatedness among Eurasian Populations , 2012, Annals of human genetics.

[38]  Ruifu Yang,et al.  Genetic Variation of the Human α-2-Heremans-Schmid Glycoprotein (AHSG) Gene Associated with the Risk of SARS-CoV Infection , 2011, PloS one.

[39]  M. Fornage,et al.  Genetic Loci Associated with Plasma Phospholipid n-3 Fatty Acids: A Meta-Analysis of Genome-Wide Association Studies from the CHARGE Consortium , 2011, PLoS genetics.

[40]  E. Levy,et al.  Genes Involved in the Metabolism of Poly-Unsaturated Fatty-Acids (PUFA) and Risk for Crohn's Disease in Children & Young Adults , 2010, PloS one.

[41]  A. El-Kadi,et al.  Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. , 2010, Pharmacology & therapeutics.

[42]  R. Totah,et al.  Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology , 2009, Expert opinion on drug metabolism & toxicology.

[43]  B. Kirby,et al.  Effects of Pregnancy on CYP3A and P‐glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study , 2008, Clinical pharmacology and therapeutics.

[44]  U. Fuhr,et al.  Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. , 2008, Pharmacogenomics.

[45]  M. Rieder,et al.  Functional polymorphism in human CYP4F2 decreases 20-HETE production. , 2007, Physiological genomics.

[46]  W. Tan,et al.  CYP2J2*7 single nucleotide polymorphism in a Chinese population. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[47]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[48]  J. Liao,et al.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. , 2005, Archives of biochemistry and biophysics.

[49]  K. Lindpaintner,et al.  Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2 , 2004, Circulation.

[50]  H. Mohrenweiser,et al.  Cloning of CYP2J2 gene and identification of functional polymorphisms. , 2002, Molecular pharmacology.

[51]  S. F. Olsen,et al.  Randomised clinical trials of fish oil supplementation in high risk pregnancies , 2000, BJOG : an international journal of obstetrics and gynaecology.

[52]  M. Ingelman-Sundberg,et al.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.

[53]  J. Lasker,et al.  Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. , 1998, The Journal of pharmacology and experimental therapeutics.

[54]  M. Rosolowsky,et al.  Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. , 1996, Biochimica et biophysica acta.

[55]  K. Tomer,et al.  Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (*) , 1996, The Journal of Biological Chemistry.

[56]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[57]  G. FitzGerald,et al.  Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Robert N. Taylor,et al.  Chapter 4 – Genetic Factors in the Etiology of Preeclampsia/Eclampsia , 2015 .

[59]  J. Falck,et al.  Red blood cells: reservoirs of cis- and trans-epoxyeicosatrienoic acids. , 2005, Prostaglandins & other lipid mediators.

[60]  Z. Dong,et al.  Renal epoxyeicosatrienoic acid synthesis during pregnancy. , 2005, American journal of physiology. Renal physiology.

[61]  G. Anderson.  Pregnancy-Induced Changes in Pharmacokinetics , 2005, Clinical pharmacokinetics.

[62]  P. Underhill,et al.  Excavating Y-chromosome haplotype strata in Anatolia , 2003, Human Genetics.

[63]  L. Harries,et al.  Molecular genetics of the human cytochrome P450 monooxygenase superfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.